What Гертикад Treats: Main Uses and Benefits

Гертикад is used to manage conditions associated with tumors that overexpress the HER2 protein. This medicine is relevant in clinical contexts involving heightened systemic burden, including HER2-overexpressing breast cancer and advanced adenocarcinoma of the stomach or the gastroesophageal junction.

For early-stage breast cancer management, its use may assist in helping with the stability of the condition following primary treatment. It is also commonly used in domains where additional symptomatic support is needed for advanced-stage disease. Furthermore, in some clinical scenarios, it is applied before surgery (neoadjuvant setting) to assist with maintaining functional stability and easing tumor management.

---

Quick Fact: Support for Condition Stability

Property	Contextual Use	Benefit Frame
Primary Indication	HER2-positive breast cancer	Contributes to supporting general well-being
Secondary Indication	Advanced gastric/GEJ cancer	Assisting with maintaining functional stability
Clinical Scenario	Before surgery (neoadjuvant)	Relevant for easing tumor management

The official eligibility rules for Гертикад (Trastuzumab) are strictly defined by regulatory authorities and govern who may be treated and under what conditions.

Absolute Contraindications

Classification	Prohibition
Hypersensitivity	Contraindicated in patients with known hypersensitivity to trastuzumab, any of the excipients, or to mouse proteins.

Eligibility and Limitations

Population Group	Regulatory Status
Adults (18+ years)	Allowed under standard conditions for approved indications (HER2-positive breast, gastric, or gastroesophageal junction cancer).
Pregnancy	Not recommended due to risk of embryo-fetal harm; effective contraception must be used during treatment and for 7 months after the final dose.
Pediatric Patients	Not established or not recommended for approved cancer indications (under 18 years).
Cardiac Dysfunction	Conditional use. Patients must undergo mandatory cardiac monitoring (LVEF assessment). Treatment must be discontinued upon development of symptomatic congestive heart failure (CHF) or a significant drop in LVEF.

Regulatory documents confirm that eligibility is conditional, particularly on cardiac health, and is restricted to the adult population who meet the HER2-positive tumor status requirement.

Interactions with other medicines and products

This section outlines the officially documented interaction profile for Гертикад (Trastuzumab), based strictly on regulatory prescribing information from governmental health authorities.

Pharmacodynamic Interaction Risks

Interacting Product Category	Regulatory Statement on Interaction
Anthracycline-Containing Regimens	Co-administration or prior use results in the highest risk and severity of cardiac dysfunction and clinical cardiac failure (CHF).
Myelosuppressive Chemotherapy	Co-administration may lead to the exacerbation of chemotherapy-induced neutropenia.

Mandatory Administration Restrictions

Regulatory labels contain specific procedural prohibitions related to drug preparation and substitution:

• Other HER2-Directed Products: There is a formal mandate not to substitute Гертикад for or with the related antibody-drug conjugates, ado-trastuzumab emtansine or fam-trastuzumab deruxtecan.
• Infusion Solutions: The product must not be mixed with other drugs or solutions in the infusion bag, and specifically must not be diluted in or administered with 5% Dextrose Injection.

Pharmacokinetic and Other Interactions

As a monoclonal antibody, Trastuzumab is cleared through catabolism. Regulatory documents confirm the lack of documented interactions with the CYP450 enzyme system, drug transporters, or specific food, alcohol, or herbal products. The interaction profile is thus primarily defined by additive toxicity and strict administration rules.

How Гертикад Works: A Dual-Action Mechanism

Гертикад (Trastuzumab) is a monoclonal antibody designed to engage a dual-action mechanism targeting cells that overexpress the HER2 protein. The drug first acts as a receptor antagonist by binding specifically to the extracellular domain of the HER2 protein, thereby preventing receptor pairing (dimerization). This binding interrupts the activation of key internal signals transmitted through downstream cellular pathways, including the PI3K/AKT and Ras/MAPK cascades.

Interrupting these molecular steps promotes cell cycle arrest and subsequently induces programmed cell death (apoptosis). Simultaneously, the drug acts as a molecular bridge: its exposed tail section is recognized by immune cells, particularly Natural Killer (NK) cells. This linkage triggers Antibody-Dependent Cellular Cytotoxicity (ADCC), a mechanism where the immune cells actively attack and destroy the targeted cells. This process modifies the cell clearance cascade by directing the innate immune system's cytotoxic function, resulting in the lysis of targeted cells.

Гертикад (Trastuzumab) is administered as a standardized clinical procedure. The medicine is primarily delivered via Intravenous (IV) infusion, requiring specialized preparation of the lyophilized powder form. An alternative administration route, Subcutaneous (SC) injection, is used for the ready-to-use co-formulation.

Dosing Regimens and Schedule

The IV administration follows weight-based dosing schedules and is administered on either a weekly or three-weekly cycle.

Regimen	Loading Dose (Initial)	Maintenance Dose (Subsequent)	Frequency
Weekly	4 mg/kg body weight	2 mg/kg body weight	Every 7 days
Three-Weekly	8 mg/kg body weight	6 mg/kg body weight	Every 21 days

For the SC formulation, a fixed dose of 600 mg is administered every three weeks.

Administration Protocol and Duration

The medicine is not given as a rapid IV push or bolus. The initial infusion of the loading dose is administered over 90 minutes. Subsequent infusions may be completed over 30 minutes if the first dose was well tolerated. The powder is diluted in 0.9% Sodium Chloride solution, as it is not compatible with Dextrose 5% solution for preparation.

For adjuvant treatment, the total duration of therapy is limited to 52 weeks (one year). For metastatic disease, treatment typically continues until a defined endpoint, such as disease progression. No specific dose adjustments are required for older adults.

Research Evidence / Overview of Studies for Гертикад

This section describes the structure of the research evidence base for Гертикад (Trastuzumab), detailing the types of studies that have been conducted for each approved use and what outcomes were examined. This is a descriptive summary of the research and does not provide clinical recommendations or predictions for individual patients.

---

Evidence for Early HER2-Positive Breast Cancer

The research base for the medicine's evaluation in early-stage breast cancer is primarily derived from several large, global Phase 3 Randomized Controlled Trials (RCTs), often followed by long-term data collection. These trials were designed to study the medicine's use when administered for a fixed time after initial therapy.

Studies focused on key survival-related measurements, including Disease-Free Survival (DFS) and Overall Survival (OS). Studies comparing patient groups receiving the medicine against those who did not, reported measurements related to disease recurrence frequency and mortality rates in the groups observed over extended follow-up (e.g., 10+ years).

Furthermore, some research explored whether shorter durations of treatment led to measurements of outcomes that were similar but not consistently equivalent when compared to the standard one-year course. Findings were mixed across different studies. A pattern reported across several trials involved an association between a longer duration of treatment and a higher measured frequency of cardiac-related changes when compared to shorter treatment courses.

Evidence for Metastatic HER2-Positive Breast Cancer

For patients with advanced (metastatic) HER2-overexpressing breast cancer, the evidence comes from pivotal Phase 3 RCTs that studied the drug in combination with chemotherapy compared to chemotherapy alone. The outcomes that were closely monitored included Overall Survival (OS) and Progression-Free Survival (PFS).

Initial trials described patterns that included differences in measured intervals for OS and PFS in the patient groups receiving the combination therapy. Research is also conducted through Biosimilar Equivalence Trials to study whether the medicine's pharmacological activity and response rates meet pre-specified equivalence criteria when compared to the original Trastuzumab product. Some retrospective reports have noted a pattern of CNS metastases that was observed at a higher frequency in patients receiving this medicine.

Key Studies & References National Cancer Institute (NIH) Drug Information: Trastuzumab Classification and Use

Common questions about Гертикад (FAQ)

Q: Does Гертикад affect the liver or kidneys?

Official safety data indicates that increases in liver enzymes (like AST/ALT) are a common adverse reaction reported in clinical studies. While specific dose adjustments are often not mandated for moderate renal (kidney) impairment, the complete overview of potential effects on these body systems is described in the official product information.

Q: Is it common to experience fatigue or drowsiness when using Гертикад?

Fatigue (feeling tired) is classified as a very common side effect reported in clinical studies. Although drowsiness itself is not always explicitly listed, the official label contains a warning regarding driving or operating machinery if symptoms like dizziness or fatigue occur.

Q: Can Гертикад be taken with common over-the-counter pain relievers?

The official interaction profile does not list specific non-prescription pain relievers as having major or moderate pharmacokinetic interactions. Since the drug is not broken down by the CYP450 enzyme system in the liver, there are typically no major or moderate documented interactions with the CYP450 enzyme system, which processes many oral medications.

Q: Is the evidence base for Гертикад considered strong by regulatory bodies?

The evidence base used to support the approval of Гертикад is primarily derived from large, global Phase 3 Randomized Controlled Trials (RCTs). This is the type of study required by regulatory agencies for drug approval to confirm a medicine's safety and effectiveness for its approved uses.

Q: Can Гертикад cause weight gain or loss?

According to the official safety profile, weight loss is classified as a common adverse reaction reported in clinical studies.

Q: What are the official warnings about stopping the use of Гертикад?

Official documents describe criteria where treatment discontinuation is required upon the development of symptomatic congestive heart failure (CHF) or a significant drop in the patient's Left Ventricular Ejection Fraction (LVEF). This is due to the risk of cardiac toxicity associated with the medicine.

Q: What does the research evidence say about the effect of Гертикад on fertility?

There are no specific human data on the effect of this medicine on fertility. However, official guidance includes a requirement for effective contraception during treatment and for a period of months after the final dose to prevent embryo-fetal harm.

Q: What does the official guidance say about missing a dose of Гертикад?

Official regulatory guidance addresses the procedure for a missed dose. The guidance details a procedure for administration after a delay, which may require a re-loading dose before resuming the maintenance schedule, depending on the time elapsed.

Q: Can breastfeeding mothers safely use Гертикад?

Use during breastfeeding is not recommended by the manufacturer. A potential risk to the newborn or infant cannot be excluded, and the official guidance includes a recommendation to avoid breastfeeding during therapy and for a period of months after the final dose.

Q: Is Гертикад a recently approved drug?

The initial (originator) Trastuzumab product was first approved by the FDA in September 1998 and the EMA in August 2000. Biosimilar copies may have been approved more recently.

Q: Does Гертикад contain common allergens like gluten or lactose?

The full list of non-active ingredients, known as excipients, is detailed in the regulatory section on composition. The purpose of this component listing is to allow for review for the presence of specific substances like gluten or lactose.

Q: Does taking Гертикад affect a person's ability to drive or operate machinery?

Some common side effects, such as dizziness or fatigue, may affect a person’s ability to drive or operate machinery. Official labeling contains a warning about the potential for certain side effects to impact these activities.

Q: Can Гертикад be used by people who have diabetes?

The official labeling does not prohibit the use of the medicine in patients with diabetes. However, diabetes is specifically identified as a risk factor for developing cardiac toxicity, and the official documents describe the need for monitoring for patients with this risk factor.

Q: What does the official label say about the risk of dependency on Гертикад?

According to official regulatory documents, there is no known potential for abuse or dependency reported for this medicine.

Q: Are there any known issues with taking Гертикад with acid-reducing medication?

Official drug interaction studies do not list a major pharmacokinetic interaction with common oral acid-reducing medications. This is generally because the medicine is administered intravenously and is not absorbed through the digestive system.

Q: What is the official statement regarding overdose of Гертикад?

Official documentation indicates there is limited experience with overdose of the medicine. The label describes that management of overdose typically focuses on close medical monitoring and supportive care to manage any symptoms that may occur.

Q: What are the main non-active ingredients in Гертикад?

The main non-active ingredients, or excipients, are substances included in the formulation alongside the active ingredient. These components are listed in the regulatory section on composition for reference.

Q: Does Гертикад interact with blood pressure medications?

The official interaction profile does not list specific blood pressure medications as a documented pharmacokinetic interaction. However, hypertension (high blood pressure) is identified as a risk factor that can increase the risk of cardiotoxicity associated with this medicine.

Storage and Disposal of Herticad

The storage and handling of Herticad (Trastuzumab), a powder for solution for infusion, must adhere to specific regulatory requirements to maintain product stability.

---

Required Storage Conditions

• Unopened Vials: Must be stored under refrigeration between 2 C and 8 C (36 F to 46 F) and kept in their original container.
• Prepared Solution: The reconstituted and diluted solution is stable for up to 24 hours when stored at 2 C to 8 C.
• Prohibited: The powder and the solution must not be frozen.

Handling and Disposal

• The medicine must be kept out of the sight and reach of children.
• Any unused portion of the product must be discarded.
• Disposal of the unused product and all related materials must be performed according to local regulatory requirements for pharmaceutical waste.